Muscarinic Acetylcholine Receptor Market Report 2026

The muscarinic acetylcholine receptor market size has grown strongly in recent years. It will grow from $1.89 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased prevalence of nervous system disorders, early research on g protein pathways, rising demand for respiratory condition treatments, growth in pharmaceutical r&d, limited selective receptor targeting options.

The muscarinic acetylcholine receptor market size is expected to see strong growth in the next few years. It will grow to $2.51 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to advances in receptor-specific drug discovery, rising investment in neurodegenerative disease therapies, expansion of personalized medicine, development of combination receptor products, increasing focus on targeted molecular modulation. Major trends in the forecast period include increasing focus on selective receptor targeting, growing demand for neurological disorder therapies, rising research in g protein-coupled receptor modulation, expansion of drug development for memory impairment, growing interest in combination receptor modulators.

The rising prevalence of neurological disorders is expected to drive the growth of the muscarinic acetylcholine receptor (mAChR) market. Neurological disorders, which affect the brain, spinal cord, and peripheral nerves, are a major global health challenge. Muscarinic acetylcholine receptors play a critical role in regulating complex behaviors such as cognition, locomotion, and reward, making them key therapeutic targets for conditions like schizophrenia, Parkinson’s disease, and epilepsy. For instance, in October 2023, according to the World Federation of Neurology, a UK-based charity, neurological disorders were the second-leading cause of death and the leading cause of disability worldwide, affecting more than 40% of the global population, with projections suggesting the number of individuals living with brain disease could nearly double by 2050. Therefore, the increasing prevalence of neurological disorders is propelling the muscarinic acetylcholine receptor market.

Major companies in the muscarinic acetylcholine receptor market are innovating new therapies to address neurological and psychiatric conditions. For example, in September 2023, Karuna Therapeutics, a US-based clinical-stage biopharmaceutical company, submitted a New Drug Application (NDA) for KarXT (xanomeline-trospium) to the FDA for the treatment of schizophrenia. This effort demonstrates the commitment of leading firms to develop novel therapies that improve cognitive and behavioral outcomes for patients with severe mental illnesses.

In August 2024, AbbVie, a US-based pharmaceutical company, acquired Cerevel Therapeutics for an undisclosed amount to expand its neuroscience portfolio. Cerevel Therapeutics specializes in developing innovative treatments targeting muscarinic acetylcholine receptors for neurological diseases such as schizophrenia, Parkinson’s disease, and epilepsy. This acquisition strengthens AbbVie’s position in addressing unmet needs in neurological care and advancing therapeutic options for complex brain disorders.

Major companies operating in the muscarinic acetylcholine receptor market are Heptares Therapeutics Ltd., Sumitomo Dainippon Pharma Co. Ltd., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc., AstraZeneca plc, Karuna Pharmaceuticals Inc., Anven AlzDx Inc., Merck & Co Inc., Eli Lilly and Co., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Astellas Pharma Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the muscarinic acetylcholine receptor market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global muscarinic acetylcholine receptor market during the forecast period. The regions covered in the muscarinic acetylcholine receptor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscarinic acetylcholine receptor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs affecting pharmaceutical ingredients, laboratory equipment, and biologics have increased production and sourcing costs in the muscarinic acetylcholine receptor market, particularly impacting regions dependent on imported chemical compounds and research tools. These tariffs slow down drug development timelines and increase retail prices in hospitals, clinics, and specialty centers. However, the market also benefits from incentives for domestic manufacturing, reduced foreign dependency, and strengthened local supply chains, supporting long-term stability and innovation in receptor-targeting therapies.

The muscarinic acetylcholine receptor market research report is one of a series of new reports that provides muscarinic acetylcholine receptor market statistics, including muscarinic acetylcholine receptor industry global market size, regional shares, competitors with a muscarinic acetylcholine receptor market share, detailed muscarinic acetylcholine receptor market segments, market trends and opportunities, and any further data you may need to thrive in the muscarinic acetylcholine receptor industry. This muscarinic acetylcholine receptor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Muscarinic acetylcholine receptors (mAChRs) are a class of G protein-coupled receptors (GPCRs) activated by the neurotransmitter acetylcholine. They are widely present throughout the body and play a key role in numerous physiological processes, especially within the central and peripheral nervous systems.

The main types of muscarinic acetylcholine receptors include M1, M4, M5, and others. The M1 receptor is one of the five muscarinic receptor subtypes, which are GPCRs that mediate the effects of acetylcholine in the body. These receptors are distributed through hospitals, clinics, retail pharmacies, online pharmacies, and specialty centers. They are applied in the treatment of conditions such as chronic obstructive pulmonary disease, attention deficit hyperactivity disorder, Alzheimer’s disease, memory impairment, psychiatric disorders, and others.

The muscarinic acetylcholine receptors market consists of sales of extracellular N-terminal segment, transmembrane domains (TM1-TM7), intracellular loops (IL1-IL3), intracellular C-terminal segment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.